GYRE THERAPEUTICS, INC. annual report, FY2016

Filing identity and reporting period

Important identity check: The supplied filing is Catalyst Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2016—not a filing by GYRE THERAPEUTICS, INC. It reports annual results; separate fourth-quarter financial results are not clearly provided in the supplied text.

Business context

Catalyst was a clinical-stage biopharmaceutical company focused primarily on engineered protease therapies for hemophilia. Its lead candidate, marzeptacog alfa (activated), had completed an intravenous Phase 1 trial; CB 2679d/ISU304 had completed IND-enabling preclinical work. The company had no approved products or product-sales revenue.

Financial performance and liquidity

R&D expense rose 94%, mainly from marzeptacog manufacturing, personnel and preclinical work. Revenue fell 77% following the end of the Pfizer collaboration; 2016 contract revenue came from ISU Abxis. Net loss increased despite $3.5 million of interest and other income, including gains from asset sales and a derivative-liability remeasurement. The company had an accumulated deficit of $148.0 million. Operating margins are not meaningful for this pre-commercial company.

At year-end, cash and cash equivalents were $10.3 million and short-term investments were $6.8 million, or $17.1 million combined. Cash used in investing activities was $1.3 million, while financing activities provided $0.9 million. Total assets were $38.1 million, total liabilities $22.0 million and stockholders’ equity $16.1 million. The filing said available resources, including subsequent stock-sale proceeds and remaining ATM capacity, were expected to fund operations for at least 12 months from filing; it also separately cited a runway through at least Q1 2018.

Redeemable convertible notes outstanding were $19.4 million, due or redeemable by February 19, 2018, and backed by $19.4 million of restricted cash. This escrowed cash is not available for ordinary operating needs. The notes bear no interest; the company reported no other debt obligations in 2016.

Material changes, outlook and risks

• In September 2016, Catalyst reduced its workforce by 10 employees (about 50%) to prioritize hemophilia programs, recording approximately $1.0 million in restructuring costs. It also sold assets and recognized gains.
• Management expected 2017 R&D expense to increase, principally due to manufacturing and clinical development of marzeptacog alfa; G&A expense was expected to be broadly consistent with 2016.
• Management planned to advance marzeptacog alfa into the Phase 2 portion of a Phase 2/3 subcutaneous prophylaxis trial in 2017, and expected ISU Abxis to start a Phase 1/2 subcutaneous trial of CB 2679d/ISU304 in Q2 2017. Subcutaneous dosing had not been tested in humans for either candidate.
• After Pfizer terminated its collaboration, Catalyst regained rights and received the Factor VIIa IND and related materials. Pfizer may receive up to $17.5 million in contingent milestones and single-digit royalties on future product sales.
• Catalyst committed up to $3.8 million to CMC for marzeptacog manufacturing development; $0.5 million had been paid and $3.3 million remained at year-end. It was seeking partners to out-license its anti-complement programs and had paused further Factor Xa work.
• Key risks include clinical failure or delay, immunogenicity, manufacturing-process transfer and supply, limited financing, reliance on ISU Abxis and other contractors, competition, reimbursement uncertainty, and intellectual-property challenges. A weak, transient anti-drug-antibody test in one Phase 1 participant was considered potentially false positive; no neutralizing antibodies were observed.
• A 1-for-15 reverse stock split took effect February 10, 2017. The company reported that it regained Nasdaq’s minimum-bid-price compliance by February 28, 2017.

Important facts for investors to verify

• Confirm the issuer identity: this is Catalyst Biosciences, not GYRE THERAPEUTICS, INC.
• Check subsequent filings for actual cash runway, post-year-end stock-sale proceeds, ATM usage and the treatment or maturity of the $19.4 million notes.
• Verify whether the stated 2017 trial starts occurred and review later clinical data, safety findings and regulatory updates.
• Track manufacturing readiness, spending against the CMC commitment, and any replacement or additional collaboration agreements.
• Assess the contingent Pfizer milestone and royalty terms, ISU Abxis obligations, and the status of the disclosed patent appeal concerning marzeptacog alfa.